Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Simple Lab Tests to Better Stratify Low Flow and Low Gradient AS Patients

Combining B-type natriuretic peptide (BNP) and high-sensitive cardiac troponin T measures undeniably helps to better stratify severe aortic stenosis patients with low flow and low gradient.  Many patients in these conditions clearly benefit from a transcatheter aortic valve replacement (TAVR) procedure, and for others it is simply useless, and given its high cost, better stratification could be of great use.  

Análisis de laboratorio sencillos para estratificar mejor el bajo flujo y bajo gradienteWe did know high BNP is associated with increased mortality in severe aortic stenosis patients (especially those with low flow and low gradient) but we ignored the incremental prognosis value of high-sensitive troponin level in these patients.

 

The study included 98 patients (74±10 years; 75% men) with low flow and low gradient aortic stenosis (ejection fraction <50% and/or stroke volume index  <35 ml/m², mean gradient <40 mmHg, indexed aortic valve area <0.6 cm²/m²), prospectively enrolled in the TOPAS trial (Truly or Pseudo-Severe Aortic Stenosis).


Read also: Direct Stenting vs. Conventional Angioplasty and Their Interaction with Thrombus Aspiration.


Patients were divided in three groups according to these levels: group 1, BNP <550 pg/ml and troponin <15 ng/ml; group 2, BNP ≥550 pg/ml or troponin ≥15 ng/ml; and group 3, with elevated levels (BNP ≥550 pg/ml and troponin ≥15 ng/ml).

 

Primary end point was all cause mortality.

 

27% of patients were found in group A, 40% in group B and 33% in group C. Two- year mortality rate was significantly higher in group C (41 ± 9%) compared against group B (23 ± 7%) and group A (5 ± 4%), (p<0.002 for all combinations).


Read also: An Effort Worth Your While: Rechanneling vs. Optimal Medical Treatment in Total Occlusions.


Group B did not show significant differences in mortality, regardless the higher level was BNP or troponin.

 

After adjusting for age, type of treatment (valve replacement or conservative treatment) associated coronary disease or ejection fraction, group C combined markers continued to be independent predictors of mortality (more than 4 times higher; p=0.023). Group B showed higher mortality compared to group A, though not significantly higher.

 

Conclusion

This study shows the use of combining BNP and troponin levels to clearly stratify these patients that, not long ago, were considered similar. High levels of these markers in the context of severe aortic stenosis with low flow and low gradient could determine the futility of aortic valve replacement.

 

Original title: B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin for Risk Stratification in Low-Flow, Low-Gradient Aortic Stenosis. A Substudy of the TOPAS Study.

Reference: Abdellaziz Dahou et al. J Am Coll Cardiol Img 2018, Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...